Supernus Pharmaceuticals shares are trading lower after Piper Sandler downgraded the stock from Overweight to Neutral and lowered its price target from $41 to $36.
Portfolio Pulse from Benzinga Newsdesk
Supernus Pharmaceuticals' stock is trading lower following a downgrade by Piper Sandler from Overweight to Neutral, with a reduced price target from $41 to $36.
September 11, 2024 | 2:39 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Supernus Pharmaceuticals' stock is experiencing a decline due to Piper Sandler's downgrade from Overweight to Neutral, along with a price target reduction from $41 to $36.
The downgrade by Piper Sandler, a reputable financial services firm, directly impacts investor sentiment, leading to a decrease in Supernus Pharmaceuticals' stock price. The reduction in the price target further reinforces the negative outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100